The government will reinforce R&D support in the pharmaceutical industry to develop 2 new global blockbuster drugs by 2027, by increasing public-private investments and expanding customized policy support.

The government also selected the institutionalization of non-face-to-face treatment and increasing the admissions quota of medical schools as key policies required to reinforce essential healthcare, and expressed its will to promote the policies promptly through the operation of a permanent consultative body.

On the 9th, the Ministry of Health and Welfare announced the above as part of its 2023 major task plan.

◆Full-fledged support to fostering the biohealth

Lee, Jeong-Hwan(junghwanss@dailypharm.com)